The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What director buying???
The most recent Director share purchase according to the RNS's published on this site, was 13th March 2023; at the Open Offer over 1 year ago.
There have been share awards and Long Term Incentive Plan take ups, but no actual share buying since then.
I doubt that we are profitable yet. Breakeven this year perhaps?
Loads of Directors buying now, a good sign. Confidence in the company as its making progress and profits.
" results were still 6 months away ", "His "6 months" seems a bit like a finger in the air"
Didn't he actually say "within the next 6 months"? Not saying that's reliable, but it's different from "in 6 months"
Thats a great video on the tech aspects (I couldn't get the link to work, easy enough to find "creo proactive on a you tube search). He's comes across as a well meaning person who wants to improve lives but not particularly keyed into the commercial side. His "6 months" seems a bit like a finger in the air comment which is fair enough.
At the first sign this company looks like hitting its targets I think I'll add in a big way. At the moment its 2% of my folio. I think the lung cancer treatment could be huge, but its going to take a while to show its clinically beneficial.
i've seen a lot of noise about when the nice guidelines are due, by their own time lines would expect it to be in march, but according to chris han**** at the proactive investor conference in jan, results were still 6 months away (at around 16.5 minutes in https://youtu.be/fm0486bmyum?si=nvdyaky1pfgnieww). think we may still have a bit of a wait, but hoping for good news when it does land
Canaccord reduced their position, they sold down
Whilst porky has a valid point that its going to be tight between ramping up sales and running out of cash he doesn't understand the product. On ADVFN he confuses it a standard endoscope. Make of that what you will.
38 weeks from June 1st is I think last week of feb. So we are at 40 weeks already. I think the timeline is an average rather than strict framework as some products are more complex than others.
The point about Creo not communicating particularly well I think is valid. But thats often the way when there is a bunch of scientists at the top. I've download a few of their brochures from their websites and its a moderately complex read, such as explaining why speedboat uses two different energy forms and how that affects operation. Its understandable to the lay person but we are not the target market.
Its a significant holding for me - they sponsor one of my friends sons junior cricket teams too. Its not without risk, but the potential is huge (the recent lung diagnose and treat in the same procedure being an excellent example). Just have to prove they can make and sell. Not guaranteed, but I think if they can show great growth and get near to breakeven before the cash runs out then getting some bridging finance should be straightforward.
9 hedge funds/ investment advisers hold.
Canaccord Genuity Wealth Management own 12.4% recent increase .
Amati Global Investors Limited 4% increased by 240%
Main broker shows 2 Analysts expect the price to increase by 162%
Porky over on VAL , drew my attention to his view.
Glad I did not read last week I am already 19% up.
This stock is on my watch list but I just can’t quite get to wanting to add it to my portfolio. Happy for the resident bulls here to try and convince me otherwise.
What’s holding me back from buying is my gut feelings on risk/ reward ratio. You see I’m looking at this thinking;
Pros - love the tech, it’s advancing in a very important sector, new versions brilliant, more advanced and better than anything else in market, massive worldwide potential, without doubt will ultimately get brought out, tick tick tick.
Cons - growth rate slower than expected. exiting tech in hospitals does the job albeit not as good as this tech but no rush to spend to update what they have hence why traction slow.
Massively loss making and burning cash at right rate of knots and my gut is telling me they won’t make break even without another raise not with the current traction rate. I cant understand why the cash burn is still this high at this stage? And finally I’m thinking the MCap is £114m no way would someone pay to acquire this at that price with the losses they are making so I’m thinking any upside to the SP is more than already priced in. Possibly I missed the boat at the 20p raise although I can’t help but feel if they do come for more cash I might still get opportunity later in the year back in the 15-20p range anyhow, can you see my problem here?
I think the lung procedure is significant. The reason for very low survival rates from long cancer is the colossal difficulty in getting into the lung. Its fern like structure makes large parts of it inaccessible for rigid devices and I know that Creo have been confident for several years that they could crack this problem. The key word is "flex". The Creo device is highly maneuverable and can reach into the lungs crevices, or at least this is how it was explained to me. Sometimes I am disappointed with Creo's PR. They did what I thought was a very poor job supporting the recent trading statement and here is another instance where Creo could have really promoted this achievement. Its the same with their annual report. Page after page of pretty dull stuff but very little of what investors really want to know, addressable markets, sales forecasts and strategy. Plus impossible to extract what their acquisitions really generate in terms of earnings. That said its nice to see the sp regaining ground.
Although I agree the article you posted involves the use of Creo's Microblate flex device, from our perspective it's not directly referred to ...pity.
I'm hopeful that a NICE MTG would be seen as an important step forward and start to generate a more immediate interest in Creo.
But to actually answer your question, yes think the NICE news would be very positive for the share price when it does land
Think it might be more to do with this news https://www.rbhh-specialistcare.co.uk/news/ion-robot-lung-tumour
Not convinced NICE stick to their own guidelines, but could be pleasantly surprised
The NICE website shows process for receiving MTG Medical Technologies Guidance to be 38 weeks. Based on 1 June assessment start date (rns'd) if process has gone ahead to schedule the output will be due about now - mid March.
Assuming a positive outcome do you folks believe this will elevate the SP?
Disappointed market not reacting to this mornings bullish up date !! Added this morning!
I believe that the lung ablation market could be huge.
Very positive RNS
Got some for 31.5p.
A little cheaper then last weeks ordears.
Another AIM gamble ,addiction & most lose. ( And its lent )
One Hardman & Co liked in an article few week back .
This stock is on my watch list but I just can’t quite get to wanting to add it to my portfolio. Happy for the resident bulls here to try and convince me otherwise.
What’s holding me back from buying is my gut feelings on risk/ reward ratio. You see I’m looking at this thinking;
Pros - love the tech, it’s advancing in a very important sector, new versions brilliant, more advanced and better than anything else in market, massive worldwide potential, without doubt will ultimately get brought out, tick tick tick.
Cons - growth rate slower than expected. exiting tech in hospitals does the job albeit not as good as this tech but no rush to spend to update what they have hence why traction slow.
Massively loss making and burning cash at right rate of knots and my gut is telling me they won’t make break even without another raise not with the current traction rate. I cant understand why the cash burn is still this high at this stage? And finally I’m thinking the MCap is £114m no way would someone pay to acquire this at that price with the losses they are making so I’m thinking any upside to the SP is more than already priced in. Possibly I missed the boat at the 20p raise although I can’t help but feel if they do come for more cash I might still get opportunity later in the year back in the 15-20p range anyhow, can you see my problem here?
The unanticipated R&D tax credit reduction actually amounted to "over £2m". Pretty "unfortunate" if the CFO is not monitoring relevant government tax changes, especially ones this significant?
The market was clearly hoping for even faster growth, but when you take the tax issue into account, the figures are satisfactory and all moving in the right direction. With breakeven now only about a year away, and clearly visible, I can't see a need for further fundraising - the trajectory seems firmly upwards over the coming months. Assuming no further similar tax hits (CFO?) then the next results should look comparatively enhanced.
This all seems positive to me, no change from what we already knew with no lag in anticipated timescales. As long as they can get the contracts with the various health care providers worldwide this should be a winner. This remains a share not ideally for widows and orphans but I’m happy to keep hold and fingers crossed my ship will come in.
Obviously i refer to the race to profitability before running out of cash. i can see how the initial response might be a little underwhelming (shares down around 5% at this time). Although there are improvements in sales and revenue they are not exactly breathtaking and despite a 10% reduction in costs they are still pretty high as is the subsequent loss. The tax credit hit of (was it 2m?) is a further blow although obviously outside the companies control. The not very well disguised elephant in the room of another placing before profitability will continue to weigh as nothing in the RNS reassures against this (or more specifically does not reassure me).
This is so close as the technology obviously works and is being successfully adopted. On a very personal level (DYOR) I see no particular reason to bail out of my small speculative holding at the moment.
"the Group remains on track to reach cash flow break even as planned, with the Company well positioned to meet its stated growth ambitions."
Thought this might rise today given the bit about breaking even. Anyone?